Literature DB >> 10681409

Markedly increased secretion of VLDL triglycerides induced by gene transfer of apolipoprotein E isoforms in apoE-deficient mice.

K Tsukamoto1, C Maugeais, J M Glick, D J Rader.   

Abstract

Apolipoprotein E (apoE) plays a key role in the receptor-mediated uptake of lipoproteins by the liver and therefore in regulating plasma levels of lipoproteins. ApoE may also facilitate hepatic secretion of very low density lipoprotein (VLDL) triglyceride (TG). We directly tested the hypothesis that reconstitution of hepatic apoE expression in adult apoE-deficient mice by gene transfer would acutely enhance VLDL-TG production and directly compared the three major human apoE isoforms using this approach. Second generation recombinant adenoviruses encoding the three major isoforms of human apoE (E2, E3, and E4) or a control virus were injected intravenously into apoE-deficient mice, resulting in acute expression of the apoE isoforms in the liver. Despite the expected decreases in total and VLDL cholesterol levels, apoE expression was associated with increased total and VLDL triglyceride levels (E2 > E4 > E3). The increase in TG levels significantly correlated with plasma apoE concentrations. In order to determine whether acute apoE expression influenced the rate of VLDL-TG production, additional experiments were performed. Three days after injection of adenoviruses, Triton WR1339 was injected to block lipolysis of TG-rich lipoproteins and VLDL-TG production rates were determined. Mice injected with control adenovirus had a mean VLDL-TG production rate of 74 +/- 7 micromol/h/kg. In contrast, VLDL-TG production rates in apoE-expressing mice were 363 +/- 162 micromol/h/kg, 286 +/- 175 micromol/h/kg, and 300 +/- 84 micromol/h/kg for apoE2, apoE3, and apoE4, respectively. The VLDL-TG production rates in apoE-expressing mice were all significantly greater than in control mice but were not significantly different from each other. In summary, acute expression of all three human apoE isoforms in livers of apoE-deficient mice markedly increased VLDL-TG production to a similar degree, consistent with the concept that apoE plays an important role in facilitating hepatic VLDL-TG production in an isoform-independent manner.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10681409

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  7 in total

Review 1.  The genetics of familial combined hyperlipidaemia.

Authors:  Martijn C G J Brouwers; Marleen M J van Greevenbroek; Coen D A Stehouwer; Jacqueline de Graaf; Anton F H Stalenhoef
Journal:  Nat Rev Endocrinol       Date:  2012-02-14       Impact factor: 43.330

Review 2.  Apolipoprotein E-induced cell signaling in the vessel wall.

Authors:  David Y Hui
Journal:  Rev Endocr Metab Disord       Date:  2004-12       Impact factor: 6.514

3.  Molecular mechanisms responsible for the differential effects of apoE3 and apoE4 on plasma lipoprotein-cholesterol levels.

Authors:  Hui Li; Padmaja Dhanasekaran; Eric T Alexander; Daniel J Rader; Michael C Phillips; Sissel Lund-Katz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02-14       Impact factor: 8.311

4.  Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome.

Authors:  Esther M M Ooi; Theodore W K Ng; Gerald F Watts; Dick C Chan; P Hugh R Barrett
Journal:  J Lipid Res       Date:  2012-08-28       Impact factor: 5.922

5.  Modulation of lipid metabolism with the overexpression of NPC1L1 in mouse liver.

Authors:  Makoto Kurano; Masumi Hara; Koichi Tsuneyama; Koji Okamoto; Naoyuki Iso-O; Teruhiko Matsushima; Kazuhiko Koike; Kazuhisa Tsukamoto
Journal:  J Lipid Res       Date:  2012-08-13       Impact factor: 5.922

6.  A practical approach to using mice in atherosclerosis research.

Authors:  Stewart C Whitman
Journal:  Clin Biochem Rev       Date:  2004-02

7.  LXR agonist increases apoE secretion from HepG2 spheroid, together with an increased production of VLDL and apoE-rich large HDL.

Authors:  Makoto Kurano; Naoyuki Iso-O; Masumi Hara; Nobukazu Ishizaka; Kyoji Moriya; Kazuhiko Koike; Kazuhisa Tsukamoto
Journal:  Lipids Health Dis       Date:  2011-08-05       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.